Tracking Who Makes Money On A Brand-Name Drug

(By Julie Appleby for Kaiser Health News)

The path of prescription drugs from the factory to the patient is complicated. KHN’s Julie Appleby explains how money flows through the system and contributes to the cost of a 30-day supply of a hypothetical brand-name medicine.  Continue reading here……

Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.